Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Other Income / Expenses history
Currency unavailable · from the income statement
No Other Income / Expenses data reported for this period type.
Other Income / Expenses vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $14.93M USD | +11.7% | — | 74.6% |
| LTM Mar 2026 | $10.66M USD | -47.6% | +36.1% | 4.9% | |
| LTM Mar 2026 | $10.56M USD | +70.0% | +86.2% | — | |
| LTM Mar 2026 | $10.27M USD | +9.2% | +15.3% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $8.41M USD | +109.1% | — | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $7.69M USD | — | — | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $745K USD | -95.5% | -4.3% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +10.4% | +25.7% | 39.8% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.